drugset / Trial / NCT00635024

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

NCT00635024

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Anti-thymocyte globulin may also make cancer cells more sensitive to melphalan. Giving anti-thymocyte globulin together with melphalan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with melphalan works in treating patients with relapsed multiple myeloma.

Timeline

Start
2008-05
Primary completion
2008-07
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 2.5 mg/kg Intravenous
Subject Melphalan Small molecule 16 mg/m2 Intravenous

Indications